$ELV · Elevance Health, Inc.
Elevance Health filed an 8-K under Item 7.01 (Regulation FD) stating officers will speak with investors and analysts this week and will reaffirm full-year 2026 guidance. The company reaffirmed shareholders' earnings guidance of at least $22.00 per diluted share, including approximately $7.00 per diluted share of net unfavorable items, and adjusted shareholders' earnings of at least $29.00 per diluted share excluding those items. It also reaffirmed a full-year 2026 benefit expense ratio of 90.2% plus or minus 50 basis points.
- FY2026 GAAP EPS guidance reaffirmed at at least $22.00 per diluted share.
- Adjusted EPS guidance reaffirmed at at least $29.00, excluding ~$7.00 of net unfavorable items.
- FY2026 benefit expense ratio guidance reaffirmed at 90.2% ±50 basis points.
- No additional adjustment items beyond those reported in Q3 2026 earnings.
- Disclosure furnished under Regulation FD, not deemed filed for Section 18 purposes.
Price data unavailable.
A routine guidance reaffirmation with no change to prior FY2026 targets, offering limited new information for investors.
_Not applicable._
Guidance reaffirmation carries standard forward-looking risks including healthcare cost/utilization trends, enrollment declines, and regulatory changes.